Stay up to date on the latest oncology and nursing conferences.
Social Health Determinants Impact Psychoneurological Symptoms in BC Survivors
Social determinants of health like transportation and financial increased the occurrence of psychoneurological symptoms in breast cancer survivors.
Intervention Tactics Enhance Outpatient Cancer Care, Reduce ED Visits
In accordance with CMS quality measures, interventions like provider/patient education and better access to care help reduce ED visits after chemotherapy.
Informing Patients on Integrative Oncology Can Enhance Supportive Care
Oncology nurses and APPs can enhance patients’ comfort by counseling patients on what integrative care is and working to make those options accessible.
Subcutaneous Nivolumab Maintains Comparable Efficacy, Safety to IV in ccRCC
The subcutaneous formulation of nivolumab showed comparable efficacy and safety to the IV formulation in advanced clear cell renal cell carcinoma.
HEART Protocol Leads to Reduction in ED Visits After Chemoradiation
Using risk assessment and nurse education in the High ED/Admission Risk Therapy (HEART) protocol reduced ED visits by 18% after chemoradiation treatment.
Kaifan Zhao, AGACNP-BC, PMHNP-BC, Wins ONN’s 2025 Extraordinary Healer® Award
The 2025 Extraordinary Healer® Award was presented during the 50th Annual Oncology Nursing Society Congress, recognizing oncology nursing professionals' dedication and impact.
Becoming Familiar With Patients’ AEs is Essential, Says Expert
Axel Stuart Merseburger, MD, PhD, explained that with TKIs like axitinib, it is necessary for oncology nurses to spend time with each patient to provide the best care.
Real-World Data Back First-Line Avelumab and Axitinib in Advanced RCC
Avelumab in combination with axitinib was found effective and safe as frontline treatment for advanced RCC in real-world findings.
Tivozanib Combo Yields Similar PROs to Monotherapy in Advanced Clear Cell RCC
Patient-reported outcomes were consistent between patients with RCC using tivozanib/nivolumab and tivozanib monotherapy according to study findings.
Dose Reductions Possible for Tivozanib With and Without Nivolumab for RCC
Katy Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose modifications for patients with RCC.
Nivolumab Combo for RCC Necessitates AE Monitoring, Awareness
According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially serious toxicities that should be closely monitored.
Proactive Onco-Coaching Linked to Higher OS in mRCC
Proactive onco-coaching did not improve QOL but was associated with improved OS in patients with metastatic renal cell carcinoma receiving TKIs and ICIs.
Cabozantinib Combo Maintains PFS for Advanced RCC at Follow-Up
New results uphold previous findings regarding the efficacy of cabozantinib, nivolumab, and ipilumumab arm for advanced renal cell carcinoma.
Nivolumab Plus Cabozantinib Effective Long-Term for Advanced RCC
Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.
High PSA Levels Before HIFU May Increase Recurrence Risk in Intermediate-Risk Prostate Cancer
Men with intermediate-risk prostate cancer and high PSA levels before HIFU treatment had a greater risk of both overall recurrence and treatment failure.
Enfortumab Vedotin and Pembrolizumab Effective in Treating Primary UTUC Lesions
Enfortumab vedotin alone and in combination with pembrolizumab showed promise in patients with upper tract urothelial carcinoma, particularly those ineligible for standard chemotherapy.
Real-World Data Support Enfortumab Vedotin for Urothelial Carcinoma Treatment
Real-world data demonstrate significant outcome improvements with enfortumab vedotin in patients with unresectable or metastatic urothelial carcinoma.
Darolutamide-ADT Combination Lengthens rPFS in mHSPC Regardless of Disease Volume
Patients with metastatic hormone-sensitive prostate cancer experienced increase rPFS and other efficacy end points with darolutamide plus ADT.
Certain AEs May Indicate Improved PFS With Enfortumab Vedotin for Urothelial Carcinoma
Improved progression-free survival in metastatic urothelial carcinoma was observed in patients experiencing neuropathy, skin rash, and hyperglycemia following enfortumab vedotin.
Benefits, Risks With EBRT Plus SADT in Intermediate-Risk Prostate Cancer
Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.
Enfortumab Vedotin May Be Safe in Ultra-Elderly Patients With Urothelial Carcinoma
Findings also suggested that an up-front dose reduction of enfortumab vedotin may benefit older patients with urothelial carcinoma.
Digital Health Tool Helps Patients With Prostate Cancer During Consultations
MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d recommend the tool to other patients.
ARASENS Trial: G-CSF Enables Full Docetaxel Dose in mHSPC
While lower relative dose intensity of docetaxel was associated with higher rates of G-CSF use and more adverse events, discontinuation rates were low across all groups.
177Lu-PSMA-617 With Enzalutamide for mCRPC Boosts OS, QOL
Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.
Clinical Practice Gaps Persist in Biomarker Testing for mCRPC Management
With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is needed to address these gaps.
Talazoparib-Enzalutamide Combo Increases OS in mCRPC
Patients with HRR-deficient metastatic castration-resistant prostate cancer saw a 14-month boost in OS and a 38% lower risk of death with talazoparib plus enzalutamide.
Sintilimab Plus Chemoradiotherapy Improves pCR Rate in Resectable, Locally Advanced ESCC
Sintilimab with neoadjuvant chemoradiotherapy enhanced pCR rates in resectable, locally advanced esophageal squamous cell carcinoma.
Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer
The combination of tislelizumab, irinotecan, paclitaxel, oxaliplatin, and 5-FU/leucovorin demonstrated promising efficacy and manageable safety in gastric and GEJ cancers.
Trastuzumab Combo Shows Numerical Survival Benefit in Gastric/GEJ Cancer
The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with HER2-positive gastric cancers enrolled in the INNOVATION trial.
Telotristat Ethyl Plus Chemo May Stabilize Weight in Metastatic PDAC
Managing weight loss with telotristat ethyl in patients with metastatic pancreatic ductal adenocarcinoma may improve survival, although further research is needed.
Neoantigen Vaccine Shows Promise In RCC-Mutated Renal Cell Carcinoma
ADCs Are “Legos,” Customize Cancer Treatment By Target, Safety
Capivasertib Break May Be Needed in Patients With Breast Cancer Experiencing Hyperglycemia
Safety Profiles to Look Out for in New Breast Cancer Treatments